Company Filing History:
2 out of 30 
1 out of 2 
1 out of 29 Years Active: 2019-2021
Title: ChiaHung Hung: Innovator in Pharmaceutical Compositions
Introduction
ChiaHung Hung is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative cancer treatments. With a total of 2 patents, his work focuses on enhancing the efficacy of cancer therapies while minimizing side effects.
Latest Patents
ChiaHung Hung's latest patents include groundbreaking pharmaceutical compositions of hydrophobic camptothecin derivatives. One of his inventions provides a method of using a topoisomerase I inhibitor in the treatment of cancer to reduce bone marrow suppression. This method involves administering an effective amount of a pharmaceutical composition that contains at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, along with at least one polyethylene glycol (PEG) conjugated phospholipid. The molar ratio of the PEG conjugated phospholipid to the hydrophobic topoisomerase I inhibitor is carefully defined, ranging from about 0.45:1 to about 1.05:1. Another patent focuses on a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or its pharmaceutically acceptable salt, aimed at inhibiting cancer cells in subjects in need of treatment.
Career Highlights
Throughout his career, ChiaHung Hung has worked with various companies, including Tlc Biopharmaceuticals, Inc. and Taiwan Liposome Company, Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical development and innovation.
Collaborations
ChiaHung Hung has collaborated with notable colleagues such as Pei Kan and Yun-Long Tseng. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
ChiaHung Hung is a distinguished inventor whose work in pharmaceutical compositions has the potential to significantly impact cancer treatment. His innovative approaches aim to improve patient outcomes while reducing adverse effects.